0001562180-21-004525.txt : 20210628
0001562180-21-004525.hdr.sgml : 20210628
20210628161852
ACCESSION NUMBER: 0001562180-21-004525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210624
FILED AS OF DATE: 20210628
DATE AS OF CHANGE: 20210628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mills Kenneth T.
CENTRAL INDEX KEY: 0001652824
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 211053610
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC.
STREET 2: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-06-24
false
0001590877
REGENXBIO Inc.
RGNX
0001652824
Mills Kenneth T.
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
true
true
false
false
President and CEO
Common Stock
2021-06-24
4
M
false
4500.00
3.76
A
285484.00
D
Common Stock
2021-06-24
4
S
false
4500.00
40.02
D
280984.00
D
Common Stock
2021-06-25
4
M
false
1500.00
3.76
A
282484.00
D
Common Stock
2021-06-25
4
S
false
1500.00
40.25
D
280984.00
D
Employee Stock Option (Right to Buy)
3.76
2021-06-24
4
M
false
4500.00
0.00
D
2025-05-18
Common Stock
4500.00
270500.00
D
Employee Stock Option (Right to Buy)
3.76
2021-06-25
4
M
false
1500.00
0.00
D
2025-05-18
Common Stock
1500.00
269000.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $40.00 to $40.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
/s/ Patrick J. Christmas as attorney-in-fact
2021-06-28